{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:10:25Z","timestamp":1763007025823,"version":"3.45.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,12]]},"DOI":"10.7759\/cureus.96715","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:06:46Z","timestamp":1763006806000},"source":"Crossref","is-referenced-by-count":0,"title":["Olezarsen: A Next-Generation Antisense Therapy for Hypertriglyceridemia and Familial Chylomicronemia Syndrome"],"prefix":"10.7759","author":[{"given":"Jace","family":"Joshy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Kumar Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhanu Priya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sartaj","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.09.016","article-title":"American Association of Clinical Endocrinology Clinical Practice Guideline on pharmacologic management of adults with dyslipidemia","volume":"31","author":"Patel SB","year":"2025","unstructured":"Patel SB, Wyne KL, Afreen S, et al.. American Association of Clinical Endocrinology Clinical Practice Guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025, 31:236-262. 10.1016\/j.eprac.2024.09.016","journal-title":"Endocr Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller M","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al.. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011, 123:2292-2333. 10.1161\/CIR.0b013e3182160726","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arteri.2020.04.001","article-title":"Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study","volume":"32","author":"Ruiz-Garc\u00eda A","year":"2020","unstructured":"Ruiz-Garc\u00eda A, Arranz-Mart\u00ednez E, L\u00f3pez-Uriarte B, et al.. Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Clin Investig Arterioscler. 2020, 32:242-255. 10.1016\/j.arteri.2020.04.001","journal-title":"Clin Investig Arterioscler"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020151","article-title":"Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer","volume":"15","author":"Morofuji Y","year":"2022","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, Tsutsumi K. Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer. Pharmaceuticals (Basel). 2022, 15:151. 10.3390\/ph15020151","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021508","article-title":"Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"8","author":"Sahebkar A","year":"2019","unstructured":"Sahebkar A, Simental-Mend\u00eda LE, Katsiki N, Reiner \u017d, Banach M, Pirro M, Atkin SL. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019, 8:e021508. 10.1136\/bmjopen-2018-021508","journal-title":"BMJ Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.933199","article-title":"Treatment of hypertriglyceridemia: a review of current options","volume":"64","author":"Vrabl\u00edk M","year":"2015","unstructured":"Vrabl\u00edk M, \u010ce\u0161ka R. Treatment of hypertriglyceridemia: a review of current options. Physiol Res. 2015, 64:S331-S340. 10.33549\/physiolres.933199","journal-title":"Physiol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna VS","year":"2008","unstructured":"Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008, 101:20B-26B. 10.1016\/j.amjcard.2008.02.029","journal-title":"Am J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray AC","year":"2019","unstructured":"Skulas-Ray AC, Wilson PW, Harris WS, et al.. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019, 140:e673-e691. 10.1161\/CIR.0000000000000709","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0253","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI)","volume":"16","author":"Jani RH","year":"2014","unstructured":"Jani RH, Pai V, Jha P, Jariwala G, Mukhopadhyay S, Bhansali A, Joshi S. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4\u2009mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI). Diabetes Technol Ther. 2014, 16:63-71. 10.1089\/dia.2013.0253","journal-title":"Diabetes Technol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2012.02516.x","article-title":"Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia","volume":"272","author":"Surendran RP","year":"2012","unstructured":"Surendran RP, Visser ME, Heemelaar S, et al.. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012, 272:185-196. 10.1111\/j.1365-2796.2012.02516.x","journal-title":"J Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes ES","year":"2024","unstructured":"Stroes ES, Alexander VJ, Karwatowska-Prokopczuk E, et al.. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024, 390:1781-1792. 10.1056\/NEJMoa2400201","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the\u00a0life span","volume":"12","author":"Williams L","year":"2018","unstructured":"Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the\u00a0life span. J Clin Lipidol. 2018, 12:908-919. 10.1016\/j.jacl.2018.04.010","journal-title":"J Clin Lipidol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2012.08.007","article-title":"Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia","volume":"6","author":"Christian JB","year":"2012","unstructured":"Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012, 6:450-461. 10.1016\/j.jacl.2012.08.007","journal-title":"J Clin Lipidol"},{"key":"ref14","unstructured":"Familial Hyperchylomicronemia Syndrome. (2025). Accessed. August 23, 2025: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551655\/."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11040982","article-title":"Volanesorsen: a new era in the treatment of severe hypertriglyceridemia","volume":"11","author":"Kolovou G","year":"2022","unstructured":"Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new era in the treatment of severe hypertriglyceridemia. J Clin Med. 2022, 11:982. 10.3390\/jcm11040982","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.12.2899384","article-title":"Volanesorsen for treatment of patients with familial chylomicronemia syndrome","volume":"54","author":"Warden BA","year":"2018","unstructured":"Warden BA, Duell PB. Volanesorsen for treatment of patients with familial chylomicronemia syndrome. Drugs Today (Barc). 2018, 54:721-735. 10.1358\/dot.2018.54.12.2899384","journal-title":"Drugs Today (Barc)"},{"key":"ref17","unstructured":"US Food and Drug Administration. Tryngolza (Olezarsen) - Full prescribing information. (2024). https.\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218614s000lbl.pdf."},{"key":"ref18","unstructured":"FDA approves drug to reduce triglycerides in adult patients with familial chylomicronemia syndrome. (2025). Accessed. August 23, 2025: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-drug-reduce-triglycerides-adult-patients-familial-chyl...."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby J","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, et al.. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014, 371:22-31. 10.1056\/NEJMoa1307095","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova A","year":"2017","unstructured":"Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017, 35:238-248. 10.1038\/nbt.3765","journal-title":"Nat Biotechnol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke ST","year":"2020","unstructured":"Crooke ST, Vickers TA, Liang XH. Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res. 2020, 48:5235-5253. 10.1093\/nar\/gkaa299","journal-title":"Nucleic Acids Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh516","article-title":"2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro","volume":"32","author":"Yoo BH","year":"2004","unstructured":"Yoo BH, Bochkareva E, Bochkarev A, Mou TC, Gray DM. 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro. Nucleic Acids Res. 2004, 32:2008-2016. 10.1093\/nar\/gkh516","journal-title":"Nucleic Acids Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash TP","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J, et al.. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014, 42:8796-8807. 10.1093\/nar\/gku531","journal-title":"Nucleic Acids Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e328352dc70","article-title":"Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production","volume":"23","author":"Yao Z","year":"2012","unstructured":"Yao Z, Wang Y. Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production. Curr Opin Lipidol. 2012, 23:206-212. 10.1097\/MOL.0b013e328352dc70","journal-title":"Curr Opin Lipidol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer AD","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018, 28:109-118. 10.1089\/nat.2018.0736","journal-title":"Nucleic Acid Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener AM","year":"2020","unstructured":"Quemener AM, Bachelot L, Forestier A, Donnou-Fournet E, Gilot D, Galibert MD. The powerful world of antisense oligonucleotides: from bench to bedside. Wiley Interdiscip Rev RNA. 2020, 11:e1594. 10.1002\/wrna.1594","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang XH","year":"2017","unstructured":"Liang XH, Sun H, Nichols JG, Crooke ST. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017, 25:2075-2092. 10.1016\/j.ymthe.2017.06.002","journal-title":"Mol Ther"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.05.004","article-title":"Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen","volume":"5","author":"Valdivielso P","year":"2024","unstructured":"Valdivielso P, Coca PI. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen. Med NY. 2024, 5:493-494. 10.1016\/j.medj.2024.05.004","journal-title":"Med NY"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n J","year":"2020","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol (Lausanne). 2020, 11:474. 10.3389\/fendo.2020.00474","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref30","unstructured":"Mechanism of Action (MoA) | TRYNGOLZA\u00ae (olezarsen) Injection. (2024). Accessed. August 31, 2025: https:\/\/tryngolzahcp.com\/about-tryngolza\/mechanism-of-action."},{"key":"ref31","unstructured":"Antisense drug technology. principles, strategies, and applications. (2024). Accessed: August 23, 2025: https:\/\/www.routledge.com\/Antisense-Drug-Technology-Principles-Strategies-and-Applications-Second-Edition\/Crooke\/p\/bo...."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2022.06.005","article-title":"Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia","volume":"16","author":"Karwatowska-Prokopczuk E","year":"2022","unstructured":"Karwatowska-Prokopczuk E, Tardif JC, Gaudet D, et al.. Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. J Clin Lipidol. 2022, 16:617-625. 10.1016\/j.jacl.2022.06.005","journal-title":"J Clin Lipidol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402309","article-title":"Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk","volume":"390","author":"Bergmark BA","year":"2024","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al.. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024, 390:1770-1780. 10.1056\/NEJMoa2402309","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.02.022","article-title":"Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: rationale and design of the Essence-TIMI 73b trial","volume":"286","author":"Bergmark BA","year":"2025","unstructured":"Bergmark BA, Marston NA, Prohaska TA, et al.. Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: rationale and design of the Essence-TIMI 73b trial. Am Heart J. 2025, 286:116-124. 10.1016\/j.ahj.2025.02.022","journal-title":"Am Heart J"},{"key":"ref35","unstructured":"Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides | Ionis Pharmaceuticals, Inc.. (2024). Accessed. August 23, 2025: https:\/\/ir.ionis.com\/news-releases\/news-release-details\/ionis-announces-positive-topline-results-essence-study-olezarsen."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2025.03.003","article-title":"Design and rationale of the CORE-TIMI\u202f72a and CORE2-TIMI\u202f72b trials of olezarsen in patients with severe hypertriglyceridemia","volume":"286","author":"Marston NA","year":"2025","unstructured":"Marston NA, Bergmark BA, Alexander VJ, et al.. Design and rationale of the CORE-TIMI\u202f72a and CORE2-TIMI\u202f72b trials of olezarsen in patients with severe hypertriglyceridemia. Am Heart J. 2025, 286:125-135. 10.1016\/j.ahj.2025.03.003","journal-title":"Am Heart J"},{"key":"ref37","unstructured":"Record History | NCT05681351 | ClinicalTrials.gov [Internet]. (2024). Accessed. August 23, 2025: https:\/\/clinicaltrials.gov\/study\/NCT05681351."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander VJ","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, et al.. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019, 40:2785-2796. 10.1093\/eurheartj\/ehz209","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab820","article-title":"Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk","volume":"43","author":"Tardif JC","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al.. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022, 43:1401-1412. 10.1093\/eurheartj\/ehab820","journal-title":"Eur Heart J"},{"key":"ref40","unstructured":"FDA approves Tryngolza for rare triglyceride disease. (2024). Accessed. August 23, 2025: https:\/\/www.managedhealthcareexecutive.com\/view\/fda-approves-tryngolza-for-rare-cholesterol-disease."},{"key":"ref41","unstructured":"FDA clears Ionis drug as first therapy for rare disease FCS | pharmaphorum. (2024). Accessed. August 23, 2025: https:\/\/pharmaphorum.com\/news\/fda-clears-ionis-drug-first-therapy-rare-disease-fcs."},{"key":"ref42","unstructured":"Savings & Access | TRYNGOLZA\u00ae (olezarsen) Injection. (2024). Accessed. August 23, 2025: https:\/\/tryngolza.com\/support-and-access\/access."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s44337-025-00329-2","article-title":"Efficacy and safety of Olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Saddique MN","year":"2025","unstructured":"Saddique MN, Thapa R, Khan Y, et al.. Efficacy and safety of Olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials. Discov Med. 2025, 2:117. 10.1007\/s44337-025-00329-2","journal-title":"Discov Med"},{"key":"ref44","unstructured":"Lipoprotein(a). progress on one of the last untreatable frontiers of cardiovascular risk. (2024). Accessed: August 23, 2025: https:\/\/consultqd.clevelandclinic.org\/lipoproteina-progress-on-one-of-the-last-untreatable-frontiers-of-cardiovascula...."},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0959","article-title":"Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial","volume":"9","author":"Gaudet D","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al.. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024, 9:620-630. 10.1001\/jamacardio.2024.0959","journal-title":"JAMA Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/430988-olezarsen-a-next-generation-antisense-therapy-for-hypertriglyceridemia-and-familial-chylomicronemia-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:06:49Z","timestamp":1763006809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/430988-olezarsen-a-next-generation-antisense-therapy-for-hypertriglyceridemia-and-familial-chylomicronemia-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7759\/cureus.96715","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}